We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · June 30, 2022

Long-Term Survival in Patients With Anaplastic Oligodendroglioma Who Received Radiotherapy Plus PCV Chemotherapy

Journal of Clinical Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors
J. Clin. Oncol 2022 Jun 22;[EPub Ahead of Print], AB Lassman, K Hoang-Xuan, MC Polley, AA Brandes, JG Cairncross, JM Kros, LS Ashby, MJB Taphoorn, L Souhami, WNM Dinjens, NN Laack, MCM Kouwenhoven, KL Fink, PJ French, DR Macdonald, D Lacombe, M Won, T Gorlia, MP Mehta, MJ van den Bent

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Brain Cancer Center of Excellence

Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.


Further Reading